Phase 2 N=74 Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
Overweight
Primary: Percent Change From Baseline in Body Weight — -2.0; -0.3 Percent change — p=0.059
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=301 Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study
Delirium · Fall Injury
Primary: Incident Delirium Rate — 6; 0 Participants
N/A N=20 Community Exercise for Fall Risk in PD
Parkinson Disease · Fall · Exercise
Primary: Number of Falls Experienced During the Study Period as Reported by Self-report — 16; 7 self-reported falls
Phase 1 N=14 A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4436.69; 4458.63 nanomole…
N/A N=35 Retention of Nasoenteric Feeding Tubes in Pediatric Patients Using a Nasal Bridle
Feeding Tube Complication
Primary: Number of Tube Dislodgements Per 10 Tube Days. — 0.16; 2.11 Dislodgements
Phase 3 N=105 An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period — 0; 20 Participants — p=< 0.0001
N/A N=54 Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) 2.0
Head and Neck Cancer
Primary: Change in Body Image Scale Score From Baseline to 1-month Post-intervention — -3.5; -0.7 score on a scale — p=0.25
Phase 2 N=264 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Chronic Kidney Diseases · Inflammation
Primary: Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels — -4.49; -76.57; -88.12; -91.64 Percent change — p=<0.0001
Phase 2 N=154 Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
Glaucoma Open-angle
Primary: IOP (mmHg) Change From Baseline at Week 12 — -8.3; -7.7; -7.5 mmHg
Phase 3 N=403 ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Treatment Resistant Depression · Electroconvulsive Therapy · ECT
Primary: Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16) — 70; 108 Participants…
N/A N=206 Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
Attention Deficit Hyperactivity Disorder
Primary: Impairment Rating Scale, Overall Impairment (Change From Baseline to Posttreatment) in Cohort 1: Stimulant — -0.7 score on a scale
Phase 4 N=450 MORDOR II Burkina Faso: Longitudinal Trial
Child Growth · Diversity of Microbiome · Child Mortality
Primary: Intestinal Microbial Diversity — 46.3; 49.5 index score
Phase 1 N=64 Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants
Phase 2 N=30 A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Progressive Metastatic Castrate-Resistant Prostate Cancer
Primary: Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel…
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)